Davidson will receive the compensation payable to the Company’s non-employee directors in accordance with the Company’s policy regarding the same, as in effect from time-to-time. Davidson and the Company entered into the Company’s standard form of director indemnification agreement upon her appointment, and Ms. In connection with her appointment to the Board, Ms. Davidson and any director or executive officer of the Company. There are no family relationships between Ms. in Pharmacy from the University of Kentucky, College of Pharmacy.
Davidson has also previously served as President of the Missouri-Illinois Gateway Hemophilia Association, from 2002 to 2003, and Vice President of the National Pharmacy Roundtable, from 1995 to 1996. (“Omnicare”), a comprehensive pharmaceutical and chronic care service provider, from 1997 to 1999, and as Chief Operating Officer of Clasen Long Term Care Pharmacy, a medical services provider, from 1989 until it was acquired by Omnicare in 1997. Davidson served as Vice President of Omnicare, Inc. Davidson, age 66, currently serves as President of Fast Scripts LLC, an early-stage medical service provider to individuals recovering from opioid addiction, a position she has held since March 2021 Co-Manager of SkiProp LLC, an owner of rental properties, a position she has held since April 2015 and Manager of Davidson LLC, an owner of various businesses and rental properties, a position she has held since 1996. No decision has been made as to the Board standing committees upon which Ms. Davidson’s appointment as a director of the Company, the size of the Board was expanded from six to seven members. (the “Company”) appointed Jill Davidson as a director of the Company. (d) Effective July 26, 2023, the Board of Directors (the “Board”) of Diffusion Pharmaceuticals Inc.
Information required by Item 1.01 of Form 8-K included in Item 5.02 of this Current Report is incorporated herein by reference.ĭeparture of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers ☐Įntry Into a Material Definitive Agreement If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Name of each exchange on which registered Securities registered pursuant to Section 12(b) of the Act: Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) (Former name or former address, if changed since last report)Ĭheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: (Registrant’s telephone number, including area code) (State or other jurisdiction of incorporation) (Exact name of registrant as specified in its charter)
Date of Report (Date of earliest event reported): July 26, 2023
0 kommentar(er)
